Clicky

IPCA LABORATORIES LTD.(IPCALAB)

Description: Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. It also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic, cardiology, dermatology, diabetes, fever, gastroenterology, hematology, helminthics, hepatoprotective, immunosuppressant, infectious disease, malarial, neurology, nutraceuticals, ophthalmology, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology, as well as products in various dosage forms comprising oral solids, powders for suspension, and liquid and dry injections. The company exports its products to approximately 100 countries worldwide. It has an agreement with Medicines for Malaria Venture to develop a novel antimalarial co-formulation named Atoguanil. The company was incorporated in 1949 and is based in Mumbai, India.


Keywords: Natural Sciences Medication Diabetes Active Pharmaceutical Ingredients Nutraceutical Allergy Fever Pharmaceutical Formulations Antimalarial Medication Ipca Laboratories

Home Page: www.ipca.com

125, Kandivli Industrial Estate
Mumbai, 400067
India
Phone: 91 22 6210 5000


Officers

Name Title
Mr. Premchand Godha Chairman, CEO & MD
Mr. Ajit Kumar Bhanwarlal Jain CFO, Joint MD & Exec. Director
Mr. Harish P. Kamath Compliance Officer, Corp. Counsel & Company Sec.
Mr. Pranay Godha Exec. Director
Mr. Prashant P. Godha Exec. Director
Mr. Pawan Kothari VP of Operations
Mr. Vishnu Saran Singh Kushwaha VP of Technical
Mr. Sunil Ghai Pres of Marketing
Mr. Sameer S. Tamhane Sr. VP of HR
Dr. Ashok Kumar Pres of R&D - Chemicals

Exchange: BSE

Country: IN

Currency: Indian Rupee (INR)

Forward PE: 0
Trailing PE: 17.9753
Price-to-Book MRQ: 3.7935
Price-to-Sales TTM: 3.7514
IPO Date:
Fiscal Year End: March
Full Time Employees: 0
Back to stocks